Evidence map›Paper›PMID 35211492›Full record

ReviewFrontiers in medicine2022

The Contribution of

Tomohiko Yamamura, Tomoko Horinouchi, Yuya Aoto, Rachel Lennon, Kandai Nozu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The heterozygous mutationFrontiers in pediatrics · 2025
    Article
  15. Case Report: Evaluation ofFrontiers in medicine · 2025
    Article
  16. Article
  17. Article
  18. A Deeper Insight intoMolecular syndromology · 2024
    Article
  19. Three exonic variants in theFrontiers in genetics · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Tomohiko YamamuraDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Tomoko HorinouchiDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Yuya AotoDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Rachel LennonWellcome Centre for Cell-Matrix Research, Faculty of Biology Medicine and Health, University of Manchester, Manchester, United Kingdom.
Kandai NozuDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe University · JPManchester Academic Health Science Centre · GBWellcome Centre for Cell-Matrix Research · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked Alport syndrome (XLAS) is caused by pathogenic variants in

Indexed as

alport syndromeCOL4A5genotype phenotype correlationminigenesplicing

Identifiers

PMID35211492
PMCPMC8861460
OpenAlexW4210840086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.